Advertisement
Supported by
International clinical trials verify the hope that reasonable and widely used medicines can help critically ill patients survive.The World Health Organization is expected to take into account new rules that encourage its use.
now i
Joe Biden is a speech that criticizes President Trump’s viral response.
International clinical trials published Wednesday showed hope that reasonable and widely used steroids could help critically ill patients with Covid-19, the disease caused by coronavirus.
Following the publication of the new data, on Wednesday the World Health Organization strongly recommended steroids for the remedy of patients with covid-19 severe or critical worldwide, but the company recommended that the drugs not be administered to patients with a benign disease.
The new studies came with knowledge research from seven randomized clinical trials comparing 3 steroids in more than 1,700 patients and concluded that the 3 drugs reduced the threat of death.
This article and 3 similar studies were published in the journal JAMA, with an editorial describing the studies as “a vital step in the treatment of patients with Covid-19”.
Corticosteroids now deserve to be the first-line remedy for critically ill patients, the authors added.The only other drug that has been shown to be effective in critically ill patients is remdesivir.
Doctors use steroids such as dexamethasone, hydrocortisone and methylprednisolone to weaken the body’s immune system, relieving inflammation, swelling and pain.Many patients with Covid-19 do not die from the virus, but from the body’s overreaction to infection.
Analysis of the aggregate knowledge that steroids were related to a one-third relief in deaths in patients with Covid-19 produced the most powerful results: a 36% reduction in deaths in 1282 patients treated in 3 separate trials.
In June, researchers at the University of Oxford discovered that dexamethasone gave the impression that survival rates in critically ill patients were hopeful that other reasonable steroids could help those patients.
Overall, the new studies will build confidence in steroid use and respond to any persistent hesitation from some doctors, said Dr. Todd Rice, associate professor and physician of extensive care at Vanderbilt University School of Medicine.
“This shows us that steroids are obviously favorable in this population and will obviously be administered, unless you can’t explain why, which will have to be a fairly rare opportunity,” he said.
Ad